Bruker (NASDAQ:BRKR) Sets New 1-Year Low After Earnings Miss

Bruker Corporation (NASDAQ:BRKR)’s share price reached a new 52-week low during mid-day trading on Monday following a dissappointing earnings announcement. The company traded as low as $32.27 and last traded at $33.45, with a volume of 1126349 shares traded. The stock had previously closed at $37.99.

The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.11). The business had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. Bruker’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 EPS.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s dividend payout ratio (DPR) is currently 38.46%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup dropped their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday. Bank of America dropped their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. The Goldman Sachs Group dropped their price objective on Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. UBS Group dropped their price target on Bruker from $57.00 to $45.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. Finally, Jefferies Financial Group dropped their price target on Bruker from $70.00 to $60.00 and set a “buy” rating for the company in a research note on Monday. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $53.10.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 27.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently modified their holdings of BRKR. Nisa Investment Advisors LLC lifted its stake in shares of Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Pinnacle Bancorp Inc. bought a new stake in shares of Bruker in the 1st quarter valued at about $29,000. Allworth Financial LP lifted its stake in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Spire Wealth Management bought a new stake in shares of Bruker in the 2nd quarter valued at about $32,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. The business has a 50 day moving average price of $39.93 and a two-hundred day moving average price of $43.20. The company has a market cap of $5.26 billion, a P/E ratio of 66.77, a price-to-earnings-growth ratio of 2.56 and a beta of 1.16.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.